伊伐布雷定联合左西孟旦对射血分数降低的心力衰竭患者的疗效观察OACSTPCD

Objective To observe the clinical efficacy of combined therapy of levosimendan and ivabradine in patients with heart failure with reduced ejection fraction(HFrEF).Methods From September 2021 to August 2023,170 HFrEF patients treated at Yulin Hospital,the First Affiliated Hospital of Xi'an Jiaotong University were divided into group A(85 cases)and group B(85 cases)by random number table method.Group A received conventional treatment plus levosimendan injection,while group B was treated with ivabradine hydrochloride tablets on the basis of group A,the treatment lasted for 2 months.Changes in left ventricular function[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),interventricular septal thickness],heart rate(HR),stroke volume(SV),and index of microcirculatory resistance(IMR)were analyzed before and after treatment.The treatment effectiveness,quality of life,and adverse reactions between the two groups were compared.Results After treatment,LVEDD,LVESD,HR,interventricular septal thickness,and IMR decreased in both groups,while SV and LVEF increased(P<0.05).Group B showed lower post-treatment LVEDD,LVESD,HR,interventricular septal thickness,and IMR and higher SV and LVEF compared to group A(t=2.810,3.460,7.300,6.857,7.950,4.600,3.743;P<0.05).The overall efficacy rate in group B(96.47%)was higher than in Group A(80.00%)(χ2=11.107,P<0.05).Quality of life scores for emotional,physical,social,role,and cognitive functions in Group B were significantly higher than those in Group A(t=22.694,7.072,11.896,10.857,17.426;P<0.05).The incidence of adverse reactions in Group B(8.24%)was lower than that in Group A(20.00%)(χ2=4.852,P<0.05).Conclusion The combination of ivabradine and levosimendan can effectively treat patients with HFrEF,improve their quality of life,and has good safety performance.